Skip to main content
. 2017 May 23;12(8):1291–1300. doi: 10.2215/CJN.05300516

Figure 4.

Figure 4.

Effect of long-term eplerenone treatment on glomerular injury. Glomerulosclerosis percentage was quantified in renal biopsy samples from placebo- or eplerenone-treated groups at 0 and 24 months. (A) FSGS, (B) global glomerulosclerosis, and (C) total glomerulosclerosis in placebo 0 (white bars), placebo 24 (squared bars), eplerenone 0 (gray bars), and eplerenone 24 (black bars). The data are expressed as mean±SD, *P<0.05 versus placebo 0 group. Ep0, eplerenone month 0; Ep24, eplerenone month 24; GS, glomerulosclerosis; P0, placebo month 0; P24, placebo month 24.